KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Weighted Average) (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $191.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 0.93% year-over-year to $191.8 million, compared with a TTM value of $191.8 million through Dec 2025, up 0.93%, and an annual FY2025 reading of $191.8 million, up 0.93% over the prior year.
  • Shares Outstanding (Weighted Average) was $191.8 million for Q4 2025 at Biomarin Pharmaceutical, roughly flat from $191.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $191.8 million in Q4 2025 and bottomed at $181.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $187.2 million, with a median of $187.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 1.45% in 2023, then increased 0.84% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $182.9 million in 2021, then grew by 1.32% to $185.3 million in 2022, then increased by 1.39% to $187.8 million in 2023, then grew by 1.17% to $190.0 million in 2024, then grew by 0.93% to $191.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BMRN at $191.8 million in Q4 2025, $191.6 million in Q3 2025, and $191.4 million in Q2 2025.